Dr. Ariel E. Marciscano is a board-certified radiation oncologist and Assistant Professor of Radiation Oncology at Weill Cornell Medicine/New York Presbyterian Hospital. He is a New York/New Jersey native. He received his undergraduate degree in Biology at Georgetown University where he was a Howard Hughes Medical Institute (HHMI) undegraduate research scholar. He received his M.D. from New York University School of Medicine during which time he studied radiosensitization of glioma via TGFbeta blockade in the Barcellos-Hoff laboratory. He completed a medical internship at Massachusetts General Hospital and residency training in radiation oncology at The Johns Hopkins Hospital. During his time at Johns Hopkins, Dr. Marciscano studied mechanisms of synergy of radiation and immunotherapy in the Bloomberg-Kimmel Institute for Cancer Immunotherapy in the laboratory of Charles G. Drake and subsequently completed a fellowship in Immunotherapy at the NCI, Center for Cancer Research. Dr. Marciscano joined the faculty at Memorial Sloan Kettering focusing on genitourinary cancers and metastatic disease with research initiatives in combining stereotactic radiation with immunotherapy for patients with metastatic cancer and developing novels methods to non-invasively treat and monitor response to stereotactic radiation. He has published several peer-reviewed manuscripts, review articles and book chapters and regularly presents his research at national and international scientific meetings.

Dr. Marciscano is currently a faculty member at Weill Cornell Medicine as Assistant Professor of Radiation Oncology. In his current role, he serves as Director of Radiation Therapy Preclinical Core (RTPC) and runs a research laboratory focusing on optimizing radiation-immunotherapy synergy, novel radiation-drug combinations and understanding the immune response to stereotactic radiation within the tumor microenvironment. He is also a member of the Radiation Oncology Clinical Research Office (ROCRO) providing a link between preclinical and clinical initiatives within the Department of Radiation Oncology.